Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. It is grouped under the following drug class(es): Psychotropic agents. Its therapeutic use is listed as antipsychotics, central nervous system (CNS) agents and mood stabilizers. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include lurasidona and lurasidonum. Its PubChem CID is 213046.
Lurasidone
| CAS No | 367514-87-2 |
|---|---|
| Molecular Formula | C28H36N4O2S |
| Molecular Weight | 492.70 g/mol |
| Synonyms | (1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
The listed CAS number is 367514-87-2.
The listed molecular formula is C28H36N4O2S.
The listed molecular weight is 492.70 g/mol.
(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione.
The source lists lurasidona and lurasidonum.